Skip to main content

Latest stock market podcasts

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Morning Bell 29 February

Bell Direct
February 29, 2024

Morning Bell 28 February

Bell Direct
February 28, 2024

Morning Bell 27 February

Bell Direct
February 27, 2024

Morning Bell 26 February

Bell Direct
February 26, 2024

Weekly Wrap 23 February

Bell Direct
February 23, 2024

Morning Bell 22 February

Bell Direct
February 22, 2024

Morning Bell 21 February

Bell Direct
February 21, 2024

Morning Bell 20 February

Bell Direct
February 20, 2024

Morning Bell 19 February

Bell Direct
February 19, 2024

Weekly Wrap 16 February

Bell Direct
February 16, 2024

Morning Bell 16 February

Bell Direct
February 16, 2024